Pfizer acquires Vicuron in $1.9B deal

Biopharma giant Pfizer is paying $1.9 billion to buy Vicuron Pharmaceuticals, a King of Prussia, Pennsylvania-based drug developer with two products under FDA review. The deal for $29.10 per share marks a 74 percent premium over Vicuron's 90-day average stock price, which closed Wednesday at $15.80 and shot up 77 percent in premarket trading. The buyout will put a number of compounds in Pfizer's pipeline, including anidulafungin for fungal infections and dalbavancin for Gram-positive infections. Dalbavancin has shown positive results in Phase III studies in complicated skin and soft tissue infections and in a Phase II study in catheter-related bloodstream infections. The product has once-weekly dosing.

"By acquiring Vicuron, we can help bring two very important new medicines to patients around the world," said Hank McKinnell, chairman and CEO of Pfizer. "This transaction builds on Pfizer's extensive experience in anti-infectives and demonstrates our commitment to strengthen and broaden our pharmaceutical business through strategic product acquisitions."

- read this story from for more

ALSO: The news boosted shares of Arpida and Basilea, both of which are developing anti-infectives. Article

Suggested Articles

After the loss of its longtime CEO at the start of the year, a morphing MorphoSys is now losing its CSO.

A new study shows how circular ecDNA outside of the chromosome in cancer cells drives oncogenes, making tumors more aggressive.

The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.